LOGIN  |  REGISTER
Chimerix

Elutia to Participate in Upcoming Investor Conferences

August 27, 2025 | Last Trade: US$0.94 0.02 1.63

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:

Cantor Global Healthcare Conference
Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date and Time: Thursday, September 4, 2025, 9:45 a.m. ET
Webcast Link: Click Here

H.C. Wainwright 27th Annual Global Investment Conference
Format: Presentation and 1x1 Meetings
Presentation Date and Time: Wednesday, September 10, 2025, 9:30 a.m. ET
Webcast Link: Click Here

Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
Format: 1x1 Meetings
Date: Thursday, September 11, 2025

Institutional investors interested in scheduling a meeting may contact their Cantor, H.C. Wainwright, or Lake Street representative or email This email address is being protected from spambots. You need JavaScript enabled to view it..

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.

This press release was published by a CLEAR® Verified individual.

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page